科研製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2023/03/20 | 3,660 | 3,680 | 3,635 | 3,645 | -35 | -1% | 63,600 |
| 2023/03/17 | 3,690 | 3,705 | 3,680 | 3,680 | +5 | +0.1% | 65,100 |
| 2023/03/16 | 3,650 | 3,685 | 3,635 | 3,675 | -40 | -1.1% | 77,500 |
| 2023/03/15 | 3,695 | 3,725 | 3,675 | 3,715 | +20 | +0.5% | 71,900 |
| 2023/03/14 | 3,700 | 3,715 | 3,640 | 3,695 | -50 | -1.3% | 66,100 |
| 2023/03/13 | 3,775 | 3,775 | 3,715 | 3,745 | -50 | -1.3% | 54,400 |
| 2023/03/10 | 3,780 | 3,820 | 3,780 | 3,795 | -20 | -0.5% | 92,200 |
| 2023/03/09 | 3,800 | 3,825 | 3,795 | 3,815 | +40 | +1.1% | 52,500 |
| 2023/03/08 | 3,720 | 3,790 | 3,715 | 3,775 | +50 | +1.3% | 81,000 |
| 2023/03/07 | 3,710 | 3,750 | 3,705 | 3,725 | +20 | +0.5% | 45,000 |
| 2023/03/06 | 3,740 | 3,740 | 3,700 | 3,705 | -5 | -0.1% | 74,300 |
| 2023/03/03 | 3,695 | 3,740 | 3,695 | 3,710 | +50 | +1.4% | 155,200 |
| 2023/03/02 | 3,650 | 3,675 | 3,630 | 3,660 | +40 | +1.1% | 96,400 |
| 2023/03/01 | 3,620 | 3,640 | 3,610 | 3,620 | -5 | -0.1% | 73,200 |
| 2023/02/28 | 3,650 | 3,665 | 3,620 | 3,625 | -40 | -1.1% | 100,400 |
| 2023/02/27 | 3,630 | 3,665 | 3,630 | 3,665 | +40 | +1.1% | 46,600 |
| 2023/02/24 | 3,615 | 3,635 | 3,605 | 3,625 | +20 | +0.6% | 42,000 |
| 2023/02/22 | 3,635 | 3,635 | 3,595 | 3,605 | -30 | -0.8% | 66,300 |
| 2023/02/21 | 3,625 | 3,640 | 3,620 | 3,635 | -5 | -0.1% | 51,100 |
| 2023/02/20 | 3,660 | 3,670 | 3,640 | 3,640 | +15 | +0.4% | 52,900 |
| 2023/02/17 | 3,620 | 3,625 | 3,610 | 3,625 | -10 | -0.3% | 35,600 |
| 2023/02/16 | 3,640 | 3,660 | 3,630 | 3,635 | -5 | -0.1% | 55,400 |
| 2023/02/15 | 3,630 | 3,650 | 3,580 | 3,640 | +30 | +0.8% | 101,700 |
| 2023/02/14 | 3,600 | 3,615 | 3,585 | 3,610 | +30 | +0.8% | 50,100 |
| 2023/02/13 | 3,605 | 3,615 | 3,575 | 3,580 | -5 | -0.1% | 35,500 |
| 2023/02/10 | 3,580 | 3,605 | 3,570 | 3,585 | ±0 | ±0% | 52,400 |
| 2023/02/09 | 3,595 | 3,615 | 3,580 | 3,585 | -30 | -0.8% | 38,300 |
| 2023/02/08 | 3,600 | 3,635 | 3,600 | 3,615 | +35 | +1% | 53,400 |
| 2023/02/07 | 3,575 | 3,620 | 3,565 | 3,580 | +35 | +1% | 59,500 |
| 2023/02/06 | 3,665 | 3,680 | 3,545 | 3,545 | -85 | -2.3% | 142,800 |
| 2023/02/03 | 3,660 | 3,680 | 3,575 | 3,630 | -60 | -1.6% | 178,300 |
| 2023/02/02 | 3,715 | 3,735 | 3,690 | 3,690 | -40 | -1.1% | 75,300 |
| 2023/02/01 | 3,780 | 3,780 | 3,730 | 3,730 | -35 | -0.9% | 35,200 |
| 2023/01/31 | 3,750 | 3,785 | 3,750 | 3,765 | +10 | +0.3% | 69,700 |
| 2023/01/30 | 3,755 | 3,765 | 3,735 | 3,755 | -20 | -0.5% | 53,200 |
| 2023/01/27 | 3,780 | 3,790 | 3,765 | 3,775 | -10 | -0.3% | 32,700 |
| 2023/01/26 | 3,805 | 3,810 | 3,765 | 3,785 | -30 | -0.8% | 57,600 |
| 2023/01/25 | 3,810 | 3,835 | 3,780 | 3,815 | -10 | -0.3% | 47,500 |
| 2023/01/24 | 3,810 | 3,840 | 3,810 | 3,825 | ±0 | ±0% | 39,700 |
| 2023/01/23 | 3,810 | 3,840 | 3,800 | 3,825 | +50 | +1.3% | 62,100 |
| 2023/01/20 | 3,780 | 3,790 | 3,760 | 3,775 | +15 | +0.4% | 35,000 |
| 2023/01/19 | 3,730 | 3,770 | 3,730 | 3,760 | +20 | +0.5% | 51,000 |
| 2023/01/18 | 3,735 | 3,770 | 3,725 | 3,740 | ±0 | ±0% | 60,400 |
| 2023/01/17 | 3,745 | 3,760 | 3,720 | 3,740 | +15 | +0.4% | 48,900 |
| 2023/01/16 | 3,690 | 3,755 | 3,690 | 3,725 | +20 | +0.5% | 46,700 |
| 2023/01/13 | 3,670 | 3,715 | 3,670 | 3,705 | +30 | +0.8% | 71,500 |
| 2023/01/12 | 3,685 | 3,685 | 3,655 | 3,675 | +15 | +0.4% | 38,100 |
| 2023/01/11 | 3,665 | 3,700 | 3,660 | 3,660 | -5 | -0.1% | 45,500 |
| 2023/01/10 | 3,710 | 3,725 | 3,665 | 3,665 | -10 | -0.3% | 69,500 |
| 2023/01/06 | 3,730 | 3,730 | 3,660 | 3,675 | -20 | -0.5% | 64,900 |
551～
600
件表示中 / 3723件
類似銘柄と比較する
現在ご覧いただいている「科研薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 科研薬 | 386,000円 | -6.4% | -71.8% | 4.92% | 43.11倍 | 0.96倍 |
|
旧理研グループの名門。導入の関節機能改善剤、自社創製の爪白癬症薬の２本柱。後発品も展開 |
| ジーエヌアイ | 378,000円 | +21.7% | +999.9% | 0.00% | 15.84倍 | 5.24倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
| 鳥居薬 | 634,000円 | +7.1% | -35.0% | 0.00% | 52.43倍 | 1.47倍 |
|
ＪＴ傘下。柱の抗ＨＩＶ薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
| 東和薬品 | 299,900円 | +7.9% | -3.3% | 2.67% | 8.34倍 | 0.86倍 |
|
後発医薬品メーカーで国内２強の一角。循環器系に強い。直販軸に発展も卸との取引を拡大中 |
| ゼリア新薬 | 203,900円 | +3.1% | -6.5% | 2.35% | 9.46倍 | 1.00倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
市場注目の銘柄
チャート関連のコラム
